Emerging research highlights the underexplored role of gut neuropeptides in Parkinson’s disease, revealing new connections ...

There was no significant difference in functional outcome between both groups at 96 weeks. 2. Exenatide was safe and ...

"Based on our research, there is promising potential for GLP-1RAs and SGLT2is to be considered for Alzheimer's disease prevention in the future. As use of these drugs continues to expand ...

A new study found that patients with type 2 diabetes treated with GLP-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors demonstrated lower risks of developing Alzheimer disease ...

It included 30 million representative Medicare beneficiaries without diabetes or cardiovascular disease and projected ... 10% one-time uptake of GLP-1 RAs, Medicare’s drug spending was projected ...

With around one million people living with Parkinson’s disease in the U.S. — and 90,000 ... to treat advanced Parkinson’s. In the phase 1 trial, the researchers used donated stem cells ...

One in eight adults have taken a glucagon-like peptide 1 (GLP-1) agonist to lose weight or to treat a comorbidity like type 2 diabetes or cardiovascular disease ... It’s important to fully ...

Right. I mean, I think GLP-1’s definitely created the foundation and created that paradigm shift in how we view weight loss and view obesity as a disease, but it is just the foundation and there’s ...

“Based on our research, there is promising potential for GLP-1RAs and SGLT2is to be considered for Alzheimer’s disease prevention in the future. As use of these drugs continues to ...